Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,151,010 papers from all fields of science
Search
Sign In
Create Free Account
Aldesleukin 22000000 UNT Injection [Proleukin]
Known as:
ALDESLEUKIN 1.1 mg in 1 mL INTRAVENOUS INJECTION [PROLEUKIN]
, Proleukin 22,000,000 UNT Injection
, aldesleukin 1.1 mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Proleukin]
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
8 relations
Aldesleukin
Injection
Mannitol
Proleukin
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes
M. N. Pham
,
M. V. von Herrath
,
J. Vela
Frontiers in Immunology
2016
Corpus ID: 17647767
Regulatory T cells (Tregs) play an important role in preventing effector T-cell (Teff) targeting of self-antigens that can lead…
Expand
2016
2016
Abstract 558: Durable antitumor activity of the CD122-biased immunostimulatory cytokine NKTR-214 combined with immune checkpoint blockade
J. Langowski
,
Rhoneil Pena
,
+5 authors
D. Charych
2016
Corpus ID: 78139056
Background: While immune checkpoint blockade is a promising therapeutic approach, combination with agents that modulate…
Expand
2014
2014
OP0104 Low-Dose Interleukin-2 Therapy Caused Selective Expansion of Regulatory T Cells Together with RAPID Reduction of Disease Activity in A Patient with Severe Refractory Sle
C. von Spee-Mayer
,
E. Siegert
,
A. Rose
,
J. Humrich
,
G. Riemekasten
2014
Corpus ID: 57338587
Background SLE is characterized by the breakdown of immune tolerance towards nuclear autoantigens. Aberrant activation of…
Expand
2014
2014
Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin® (HD IL-2) and Ipilimumab Yervoy® ) in patients with metastatic melanoma (proclivity 02)
S. Patel
,
M. Milhem
,
+7 authors
W. Sharfman
Journal of Immunotherapy for Cancer
2014
Corpus ID: 31976145
Meeting abstracts To investigate whether the sequence of HD IL-2 and a checkpoint inhibitor, Ipilimumab, will have additive or…
Expand
2014
2014
A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01)
Joseph I. Clark
,
L. Flaherty
,
+15 authors
D. Lawson
Journal of Immunotherapy for Cancer
2014
Corpus ID: 12923484
Meeting abstracts To investigate whether the Vemurafenib-induced increased tumor antigen expression, T lymphocyte infiltration…
Expand
2011
2011
Prognostic significance of peripheral blood CD8highCD57+ lymphocytes in bladder carcinoma patients after intravesical IL-2.
D. Characiejus
,
V. Pašukonienė
,
+6 authors
W. den Otter
Anticancer Research
2011
Corpus ID: 12602528
BACKGROUND The objective of this study was to evaluate the recurrence-preventing effect of intravesical instillations of…
Expand
2004
2004
Comparison of Pharmacokinetics and Pharmacodynamics of two different dosing regimens of Proleukin® (IL-2) in Combination with rituximab: The effect of NK cell expansion.
S. Milan
,
D. Hurst
,
G. Michelson
,
E. Samara
2004
Corpus ID: 79375011
Background: Published results from studies testing two different dosing regimens of IL-2 in combination with rituximab have shown…
Expand
2004
2004
Investigation of FcγR Polymorphisms and Response to IL-2 (Proleukin®) and Rituximab Treatment in Rituximab-Resistant NHL Patients: Importance of the F/F Polymorphism at Position 158 of the Fcγ.
S. Milan
,
Susan E. Wilson
,
K. Kahn
,
H. Giordano
2004
Corpus ID: 79146058
Background: Antibody-dependent cellular cytotoxicty (ADCC) is an important mechanism of rituximab activity. Genetic polymorphisms…
Expand
2002
2002
Persistierende knotige Lokalreaktion mit Lymphom-ähnlichen Infiltraten nach s.c-Injektion von Interleukin-2
K. Assmann
,
D. Nashan
,
S. Grabbe
,
T. Luger
,
D. Metze
Der Hautarzt
2002
Corpus ID: 936244
ZusammenfassungInterleukin-2 (IL-2) kommt aufgrund seiner immunstimulatorischen Wirkung auf T-Zellen in der Tumortherapie von…
Expand
1994
1994
Treatment of Patients with Metastatic Renal Cell Carcinoma with Subcutaneous Recombinant Interferon-Alpha 2b and Continuous Infusion of Recombinant lnterleukin-2: A Phase II Study
R. Morant
,
J. Richner
,
M. Aapro
,
P. Palmer
,
H. Senn
1994
Corpus ID: 71326942
Background: On the basis of encouraging preclinical data, we investigated the combination of the 2 agents recombinant interferon…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE